The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1430
Hydrocodone/Chlorpheniramine (Vituz)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An oral solution (Vituz – Hawthorne) containing two old drugs, the centrally-acting opioid hydrocodone bitartrate and the first-generation H1-antihistamine chlorpheniramine maleate, has been approved by the FDA for relief of cough and [other] symptoms associated with upper respiratory allergies or a common cold in adults. Several extended-release products containing hydrocodone and chlorpheniramine are available as capsules and suspensions and have been used for years for similar indications. Vituz is classified as a schedule III controlled substance, but the FDA has asked the DEA to reclassify hydrocodone products as schedule II.

DRUGS FOR COUGH — Antitussives – Acute cough generally does not require treatment with drugs, especially in children, and suppression of productive cough may be harmful. Centrally-acting antitussives shown to be effective for cough include codeine, hydrocodone, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Hydrocodone Chlorpheniramine (Vituz)
Article code: 1430c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian